You are here: Industry Insights > Etesevimab

News List

Lilly's Bamlanivimab and Etesevimab Gain EUA for Pediatric Use contractpharma
December 07, 2021
Expanded authorization based on safety and efficacy in phase 2/3 BLAZE-1 trial in mild to moderate COVID-19 and high risk patients.
Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 prnewswire
September 22, 2021
Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19.
Lilly India gets nod for restricted EU of monoclonal antibody drugs, bamlanivimab and etesevimab to treat COVID-19 expresspharma
June 02, 2021
Bamlanivimab and etesevimab together have been authorised under Emergency Use Authorization in the US and select EU countries, for the treatment of mild to moderate COVID-19.
Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries worldpharmanews
May 11, 2021
Eli Lilly and Company is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic.
Monoclonal antibodies against COVID-19 have high potential, but efficacy against emerging variants muddled: GlobalData expresspharma
April 23, 2021
The prevalence of more transmissible strains is growing fast and may require adjustments to current therapies to ensure they retain clinical efficacy.
Lilly Modifies Purchase Agreement with U.S. for COVID Therapies contractpharma
April 13, 2021
Bamlanivimab and etesevimab agreement modified to enable the supply of etesevimab to complement doses of bamlanivimab the U.S. government already purchased.
Lilly’s bamlanivimab plus etesevimab cut death, hospitalisations for early COVID-19 in Phase III trial expresspharma
March 11, 2021
Results support use of bamlanivimab 700 mg and etesevimab 1400 mg, the dose authorised in the US and several other countries.
EMA Issues Advice on bamlanivimab Alone, Administered Together with etesevimab for COVID-19 in EU americanpharmaceuticalreview
March 10, 2021
Eli Lilly and Company announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab.
CHMP issues positive opinion for Lilly’s COVID-19 antibodies pharmatimes
March 08, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Eli Lilly’s COVID-19 antibodies bamlanivimab and etesevimab.
U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail contractpharma
March 02, 2021
The U.S. government will purchase a minimum of 100,000 doses of Lilly’s bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together.

Previous page 1 2 Next page